Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population
Prognostic factors for immune checkpoint inhibitor (CPI) response in gynecologic cancer are limited. This retrospective study aimed to identify prognostic factors associated with improved overall response rate (ORR) and progression free survival (PFS) in gynecologic cancer patients receiving at leas...
Saved in:
Main Authors: | Michelle L. Kuznicki (Author), Carrie Bennett (Author), Meng Yao (Author), Amy Joehlin-Price (Author), Peter G. Rose (Author), Haider Mahdi (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
by: Yanna Lei, et al.
Published: (2022) -
Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis
by: Yana Yang, et al.
Published: (2024) -
Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
by: Li Wang, et al.
Published: (2021) -
Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
by: Na Li, et al.
Published: (2023) -
42 Evaluation of pseudoprogression on immune checkpoint inhibitor therapy in gynecologic cancers
by: Adeola Akapo, et al.
Published: (2023)